Nemtabrutinib + Venetoclax + Rituximab
Phase 3RecruitingInterest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Leukemia, Lymphocytic, Chronic, B-Cell
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
Trial Timeline
Aug 8, 2023 → Jul 1, 2035
NCT ID
NCT05947851About Nemtabrutinib + Venetoclax + Rituximab
Nemtabrutinib + Venetoclax + Rituximab is a phase 3 stage product being developed by Merck for Leukemia, Lymphocytic, Chronic, B-Cell. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05947851. Target conditions include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Lymphocytic, Chronic, B-Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05947851 | Phase 3 | Recruiting |
Competing Products
20 competing products in Leukemia, Lymphocytic, Chronic, B-Cell